Catalyst Pharmaceuticals (NASDAQ:CPRX) Rating Increased to Strong-Buy at StockNews.com

Catalyst Pharmaceuticals (NASDAQ:CPRX) was upgraded by equities researchers at StockNews.com from a “buy” rating to a “strong-buy” rating in a research note issued on Friday.

Several other research analysts have also recently weighed in on the company. Stephens initiated coverage on Catalyst Pharmaceuticals in a research report on Monday, November 18th. They set an “overweight” rating and a $35.00 price objective on the stock. Truist Financial raised their price target on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, November 11th. Finally, HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, November 8th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Catalyst Pharmaceuticals has a consensus rating of “Buy” and an average price target of $31.14.

Catalyst Pharmaceuticals Stock Down 1.0 %

Shares of Catalyst Pharmaceuticals stock traded down $0.21 on Friday, hitting $21.31. The stock had a trading volume of 564,099 shares, compared to its average volume of 713,299. The stock has a market cap of $2.54 billion, a price-to-earnings ratio of 18.06, a price-to-earnings-growth ratio of 3.35 and a beta of 0.75. The business’s 50 day moving average is $21.80 and its two-hundred day moving average is $19.73. Catalyst Pharmaceuticals has a twelve month low of $13.12 and a twelve month high of $24.27.

Insiders Place Their Bets

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 12,000 shares of the firm’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total value of $272,640.00. Following the sale, the insider now owns 51,391 shares of the company’s stock, valued at approximately $1,167,603.52. This trade represents a 18.93 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Steve Miller sold 50,000 shares of the business’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total value of $1,096,500.00. Following the transaction, the insider now directly owns 686,996 shares of the company’s stock, valued at $15,065,822.28. This trade represents a 6.78 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 79,500 shares of company stock worth $1,754,140 over the last ninety days. Corporate insiders own 11.00% of the company’s stock.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. GAMMA Investing LLC lifted its stake in shares of Catalyst Pharmaceuticals by 62.1% in the 3rd quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 681 shares during the last quarter. nVerses Capital LLC acquired a new position in Catalyst Pharmaceuticals in the third quarter valued at approximately $50,000. Larson Financial Group LLC lifted its position in shares of Catalyst Pharmaceuticals by 27,218.2% during the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock valued at $60,000 after acquiring an additional 2,994 shares during the period. Meeder Asset Management Inc. bought a new position in shares of Catalyst Pharmaceuticals during the 2nd quarter worth about $70,000. Finally, Quantbot Technologies LP bought a new position in Catalyst Pharmaceuticals in the third quarter worth approximately $151,000. 79.22% of the stock is currently owned by institutional investors and hedge funds.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.